Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients
Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells,...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Jaunalksne, Inta [verfasserIn] |
|---|
| Format: |
Artikel |
|---|
| Erschienen: |
2009 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
no copyright information available |
|---|
| Übergeordnetes Werk: |
Enthalten in: Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. - Versita, 1994, 63(2009), 4-5 vom: 01. Jan., Seite 163-167 |
|---|---|
| Übergeordnetes Werk: |
volume:63 ; year:2009 ; number:4-5 ; day:01 ; month:01 ; pages:163-167 |
| Links: |
|---|
| DOI / URN: |
10.2478/v10046-009-0052-3 |
|---|
| Katalog-ID: |
OLC2139307313 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2139307313 | ||
| 003 | DE-627 | ||
| 005 | 20230810095224.0 | ||
| 007 | tu | ||
| 008 | 230810s2009 xx ||||| 00| ||und c | ||
| 024 | 7 | |a 10.2478/v10046-009-0052-3 |2 doi | |
| 035 | |a (DE-627)OLC2139307313 | ||
| 035 | |a (DE-B1597)v10046-009-0052-3-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 082 | 0 | 4 | |a 050 |q VZ |
| 100 | 1 | |a Jaunalksne, Inta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a no copyright information available | ||
| 520 | |a Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. | ||
| 520 | |a Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. | ||
| 650 | 4 | |a HHV-6 | |
| 650 | 4 | |a HHV-7 | |
| 650 | 4 | |a gastrointestinal cancer | |
| 650 | 4 | |a cellular immunity | |
| 700 | 1 | |a Doniņa, Simona |4 aut | |
| 700 | 1 | |a Čapenko, Svetlana |4 aut | |
| 700 | 1 | |a Čstjakovs, Maksims |4 aut | |
| 700 | 1 | |a Murovska, Modra |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. |d Versita, 1994 |g 63(2009), 4-5 vom: 01. Jan., Seite 163-167 |w (DE-627)182483487 |w (DE-600)1209542-4 |w (DE-576)045288631 |x 1407-009X |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2009 |g number:4-5 |g day:01 |g month:01 |g pages:163-167 |
| 856 | 4 | 1 | |u https://doi.org/10.2478/v10046-009-0052-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OPC-BAL | ||
| 912 | |a GBV_ILN_70 | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2009 |e 4-5 |b 01 |c 01 |h 163-167 | ||
| author_variant |
i j ij s d sd s č sč m č mč m m mm |
|---|---|
| matchkey_str |
article:1407009X:2009----::ellrmuiynuahrevrssadifcegsri |
| hierarchy_sort_str |
2009 |
| publishDate |
2009 |
| allfields |
10.2478/v10046-009-0052-3 doi (DE-627)OLC2139307313 (DE-B1597)v10046-009-0052-3-p DE-627 ger DE-627 rakwb 050 VZ Jaunalksne, Inta verfasserin aut Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients 2009 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier no copyright information available Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. HHV-6 HHV-7 gastrointestinal cancer cellular immunity Doniņa, Simona aut Čapenko, Svetlana aut Čstjakovs, Maksims aut Murovska, Modra aut Enthalten in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. Versita, 1994 63(2009), 4-5 vom: 01. Jan., Seite 163-167 (DE-627)182483487 (DE-600)1209542-4 (DE-576)045288631 1407-009X nnns volume:63 year:2009 number:4-5 day:01 month:01 pages:163-167 https://doi.org/10.2478/v10046-009-0052-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OPC-BAL GBV_ILN_70 AR 63 2009 4-5 01 01 163-167 |
| spelling |
10.2478/v10046-009-0052-3 doi (DE-627)OLC2139307313 (DE-B1597)v10046-009-0052-3-p DE-627 ger DE-627 rakwb 050 VZ Jaunalksne, Inta verfasserin aut Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients 2009 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier no copyright information available Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. HHV-6 HHV-7 gastrointestinal cancer cellular immunity Doniņa, Simona aut Čapenko, Svetlana aut Čstjakovs, Maksims aut Murovska, Modra aut Enthalten in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. Versita, 1994 63(2009), 4-5 vom: 01. Jan., Seite 163-167 (DE-627)182483487 (DE-600)1209542-4 (DE-576)045288631 1407-009X nnns volume:63 year:2009 number:4-5 day:01 month:01 pages:163-167 https://doi.org/10.2478/v10046-009-0052-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OPC-BAL GBV_ILN_70 AR 63 2009 4-5 01 01 163-167 |
| allfields_unstemmed |
10.2478/v10046-009-0052-3 doi (DE-627)OLC2139307313 (DE-B1597)v10046-009-0052-3-p DE-627 ger DE-627 rakwb 050 VZ Jaunalksne, Inta verfasserin aut Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients 2009 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier no copyright information available Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. HHV-6 HHV-7 gastrointestinal cancer cellular immunity Doniņa, Simona aut Čapenko, Svetlana aut Čstjakovs, Maksims aut Murovska, Modra aut Enthalten in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. Versita, 1994 63(2009), 4-5 vom: 01. Jan., Seite 163-167 (DE-627)182483487 (DE-600)1209542-4 (DE-576)045288631 1407-009X nnns volume:63 year:2009 number:4-5 day:01 month:01 pages:163-167 https://doi.org/10.2478/v10046-009-0052-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OPC-BAL GBV_ILN_70 AR 63 2009 4-5 01 01 163-167 |
| allfieldsGer |
10.2478/v10046-009-0052-3 doi (DE-627)OLC2139307313 (DE-B1597)v10046-009-0052-3-p DE-627 ger DE-627 rakwb 050 VZ Jaunalksne, Inta verfasserin aut Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients 2009 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier no copyright information available Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. HHV-6 HHV-7 gastrointestinal cancer cellular immunity Doniņa, Simona aut Čapenko, Svetlana aut Čstjakovs, Maksims aut Murovska, Modra aut Enthalten in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. Versita, 1994 63(2009), 4-5 vom: 01. Jan., Seite 163-167 (DE-627)182483487 (DE-600)1209542-4 (DE-576)045288631 1407-009X nnns volume:63 year:2009 number:4-5 day:01 month:01 pages:163-167 https://doi.org/10.2478/v10046-009-0052-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OPC-BAL GBV_ILN_70 AR 63 2009 4-5 01 01 163-167 |
| allfieldsSound |
10.2478/v10046-009-0052-3 doi (DE-627)OLC2139307313 (DE-B1597)v10046-009-0052-3-p DE-627 ger DE-627 rakwb 050 VZ Jaunalksne, Inta verfasserin aut Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients 2009 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier no copyright information available Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. HHV-6 HHV-7 gastrointestinal cancer cellular immunity Doniņa, Simona aut Čapenko, Svetlana aut Čstjakovs, Maksims aut Murovska, Modra aut Enthalten in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. Versita, 1994 63(2009), 4-5 vom: 01. Jan., Seite 163-167 (DE-627)182483487 (DE-600)1209542-4 (DE-576)045288631 1407-009X nnns volume:63 year:2009 number:4-5 day:01 month:01 pages:163-167 https://doi.org/10.2478/v10046-009-0052-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OPC-BAL GBV_ILN_70 AR 63 2009 4-5 01 01 163-167 |
| source |
Enthalten in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 63(2009), 4-5 vom: 01. Jan., Seite 163-167 volume:63 year:2009 number:4-5 day:01 month:01 pages:163-167 |
| sourceStr |
Enthalten in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 63(2009), 4-5 vom: 01. Jan., Seite 163-167 volume:63 year:2009 number:4-5 day:01 month:01 pages:163-167 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
HHV-6 HHV-7 gastrointestinal cancer cellular immunity |
| dewey-raw |
050 |
| isfreeaccess_bool |
false |
| container_title |
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. |
| authorswithroles_txt_mv |
Jaunalksne, Inta @@aut@@ Doniņa, Simona @@aut@@ Čapenko, Svetlana @@aut@@ Čstjakovs, Maksims @@aut@@ Murovska, Modra @@aut@@ |
| publishDateDaySort_date |
2009-01-01T00:00:00Z |
| hierarchy_top_id |
182483487 |
| dewey-sort |
250 |
| id |
OLC2139307313 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">OLC2139307313</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230810095224.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">230810s2009 xx ||||| 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2478/v10046-009-0052-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2139307313</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-B1597)v10046-009-0052-3-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">050</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jaunalksne, Inta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">no copyright information available</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HHV-6</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HHV-7</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gastrointestinal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cellular immunity</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doniņa, Simona</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Čapenko, Svetlana</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Čstjakovs, Maksims</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Murovska, Modra</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.</subfield><subfield code="d">Versita, 1994</subfield><subfield code="g">63(2009), 4-5 vom: 01. Jan., Seite 163-167</subfield><subfield code="w">(DE-627)182483487</subfield><subfield code="w">(DE-600)1209542-4</subfield><subfield code="w">(DE-576)045288631</subfield><subfield code="x">1407-009X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:63</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:4-5</subfield><subfield code="g">day:01</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:163-167</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.2478/v10046-009-0052-3</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BAL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">63</subfield><subfield code="j">2009</subfield><subfield code="e">4-5</subfield><subfield code="b">01</subfield><subfield code="c">01</subfield><subfield code="h">163-167</subfield></datafield></record></collection>
|
| author |
Jaunalksne, Inta |
| spellingShingle |
Jaunalksne, Inta ddc 050 misc HHV-6 misc HHV-7 misc gastrointestinal cancer misc cellular immunity Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients |
| authorStr |
Jaunalksne, Inta |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)182483487 |
| format |
Article |
| dewey-ones |
050 - General serial publications |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
OLC |
| remote_str |
false |
| illustrated |
Not Illustrated |
| issn |
1407-009X |
| topic_title |
050 VZ Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients HHV-6 HHV-7 gastrointestinal cancer cellular immunity |
| topic |
ddc 050 misc HHV-6 misc HHV-7 misc gastrointestinal cancer misc cellular immunity |
| topic_unstemmed |
ddc 050 misc HHV-6 misc HHV-7 misc gastrointestinal cancer misc cellular immunity |
| topic_browse |
ddc 050 misc HHV-6 misc HHV-7 misc gastrointestinal cancer misc cellular immunity |
| format_facet |
Aufsätze Gedruckte Aufsätze |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
nc |
| hierarchy_parent_title |
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. |
| hierarchy_parent_id |
182483487 |
| dewey-tens |
050 - Magazines, journals & serials |
| hierarchy_top_title |
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)182483487 (DE-600)1209542-4 (DE-576)045288631 |
| title |
Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients |
| ctrlnum |
(DE-627)OLC2139307313 (DE-B1597)v10046-009-0052-3-p |
| title_full |
Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients |
| author_sort |
Jaunalksne, Inta |
| journal |
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. |
| journalStr |
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. |
| isOA_bool |
false |
| dewey-hundreds |
000 - Computer science, information & general works |
| recordtype |
marc |
| publishDateSort |
2009 |
| contenttype_str_mv |
txt |
| container_start_page |
163 |
| author_browse |
Jaunalksne, Inta Doniņa, Simona Čapenko, Svetlana Čstjakovs, Maksims Murovska, Modra |
| container_volume |
63 |
| class |
050 VZ |
| format_se |
Aufsätze |
| author-letter |
Jaunalksne, Inta |
| doi_str_mv |
10.2478/v10046-009-0052-3 |
| dewey-full |
050 |
| title_sort |
cellular immunity in human herpes viruses 6 and 7 infected gastrointestinal cancer patients |
| title_auth |
Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients |
| abstract |
Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. no copyright information available |
| abstractGer |
Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. no copyright information available |
| abstract_unstemmed |
Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed. Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli. no copyright information available |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OPC-BAL GBV_ILN_70 |
| container_issue |
4-5 |
| title_short |
Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients |
| url |
https://doi.org/10.2478/v10046-009-0052-3 |
| remote_bool |
false |
| author2 |
Doniņa, Simona Čapenko, Svetlana Čstjakovs, Maksims Murovska, Modra |
| author2Str |
Doniņa, Simona Čapenko, Svetlana Čstjakovs, Maksims Murovska, Modra |
| ppnlink |
182483487 |
| mediatype_str_mv |
n |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2478/v10046-009-0052-3 |
| up_date |
2024-07-03T19:38:01.700Z |
| _version_ |
1803587925261156352 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">OLC2139307313</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230810095224.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">230810s2009 xx ||||| 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2478/v10046-009-0052-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2139307313</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-B1597)v10046-009-0052-3-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">050</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jaunalksne, Inta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">no copyright information available</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cellular Immunity in Human Herpes Viruses 6 and 7 Infected Gastrointestinal Cancer Patients CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natural killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition, however, even a tumour designated by pathologists to be early stage may be late stage when considered by the immune system. Certainly, even early stage tumours have evaded immune control, suggesting that they have acquired many immunosuppressive characteristics. The aim of the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95 gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8, CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7 presence using a nested polymerase chain reaction method. Our data showed no statistically significant difference in immunocompetent cell level between negative, latent and active HHV-6, HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a tendency to decreased $ CD4^{+} $, $ CD19^{+} $ absolute count. It may be suggested that virus-mediated immune response inhibition seems to be similar to cancer mediated, but differences in immune response among the same group of individuals had no influence on the average number of the immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, individual interpretation of each case is needed.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Šūnu Imunitāte Ar HHV-6 UN HHV-7 Inficētiem Zarnu Trakta Vēža Pacientiem Cilvēka herpes vīrusus konstatē cilvēkiem ar kompromitētu imūno atbildi. Herpes vīrusi spēj inficēt dažādas šūnas, ietekmējot gan šūnu, gan humorālo imunatbildi. HHV-6 un HHV-7 vīrusi spēj inficēt CD4 + T limfocītus, kā arī inficēt monocītus, makrofāgus, naturālos killerus, epitēlija, endotēlija, nervu šūnas un fibroblastus. Patologu noteiktā audzēja stadija ne vienmēr saskan ar imūnas sistēmas atbildes spēju, un jau agrīnās stadijās audzējs spēj pats radīt imūnsupresīvu vidi. Darba mērķis bija noskaidrot β herpes vīrusu ietekmi uz šūnu imūno atbildi. 95 kuņga zarnu trakta vēža pacientiem noteicām CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolūto šūnu līmeni, izmantojot lāzera plūsmas citoflorometrijas metodi. HHV-6, HHV-7 vīrusu klātbūtni noteicām ar nPCR metodi. Pacientiem ar negatīvu, latentu, aktīvu HHV-6, HHV-7 infekciju nekonstatējām statistiski ticamu diferenci noteikto imūnkompetento šūnu līmenī. Pacientiem ar kompromitētu imūno atbildi konstatējām zemāku CD4, CD19 absolūto skaitu. Audzēja mediētā imūnā atbilde ir līdzvērtīga imūnatbildei pacientiem ar HHV-6, HHV-7 aktīvu infekciju un limpopēniju. Viena tipa (latenta, aktīva pasīva) HHV-6, HHV-7 infekcijas pacientiem grupas robežās varam konstatēt atšķirīgu imūnatbildi katram indivīdam, taču tas neietekmē grupas vidējos rādītājus. Tāpēc uzskatām, ka ir nepieciešams izvērtēt imūnatbildi katram pacientam individuāli.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HHV-6</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HHV-7</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gastrointestinal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cellular immunity</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doniņa, Simona</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Čapenko, Svetlana</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Čstjakovs, Maksims</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Murovska, Modra</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.</subfield><subfield code="d">Versita, 1994</subfield><subfield code="g">63(2009), 4-5 vom: 01. Jan., Seite 163-167</subfield><subfield code="w">(DE-627)182483487</subfield><subfield code="w">(DE-600)1209542-4</subfield><subfield code="w">(DE-576)045288631</subfield><subfield code="x">1407-009X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:63</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:4-5</subfield><subfield code="g">day:01</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:163-167</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.2478/v10046-009-0052-3</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BAL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">63</subfield><subfield code="j">2009</subfield><subfield code="e">4-5</subfield><subfield code="b">01</subfield><subfield code="c">01</subfield><subfield code="h">163-167</subfield></datafield></record></collection>
|
| score |
7.4006968 |